• Citer

Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.

par Shagera, Qaid Ahmed ;Karfis, Ioannis ;Sideris, Spyridon ;Guiot, Thomas ;Woff, Erwin ;Chanzá, Nieves Martinez;Roumeguere, Thierry ;Gil, Thierry ;Flamen, Patrick ;Artigas, Carlos
Référence Clinical nuclear medicine, 48, 9, page (775-780)
Publication Publié, 2023-09

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Auteur:	Shagera, Qaid Ahmed; Karfis, Ioannis; Sideris, Spyridon; Guiot, Thomas; Woff, Erwin; Chanzá, Nieves Martinez; Roumeguere, Thierry; Gil, Thierry; Flamen, Patrick; Artigas, Carlos
Informations sur la publication:	Clinical nuclear medicine, 48, 9, page (775-780)
Statut de publication:	Publié, 2023-09
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Male
	Humans
	Prognosis
	Prostatic Neoplasms, Castration-Resistant -- diagnostic imaging -- drug therapy
	Positron Emission Tomography Computed Tomography -- methods
	Retrospective Studies
	Tumor Burden
	Prostate-Specific Antigen
	Treatment Outcome
	Heterocyclic Compounds, 1-Ring -- therapeutic use
	Dipeptides -- therapeutic use
	Lutetium -- therapeutic use
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0363-9762
	info:doi/10.1097/RLU.0000000000004763
	info:pii/00003072-990000000-00625
	info:scp/85166701670
	info:pmid/37385221